Nabriva Therapeutics AG plans to buck conventional thinking for antibiotic stewardship with the commercialization strategy for lefamulin, a potential first-in-class pleuromutilin antibiotic in development for community-acquired bacterial pneumonia. The company is aiming to position the antibiotic as a first-line option to treat CABP, rather than as an antibiotic to be held in reserve for only the sickest patients.
The strategy is precisely in-line with the over-arching theme of antibiotic stewardship, because of the targeted nature of